{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T23:10:05Z","timestamp":1751929805603,"version":"3.41.2"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"DOI":"10.7759\/cureus.87475","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T22:43:38Z","timestamp":1751928218000},"source":"Crossref","is-referenced-by-count":0,"title":["Enterocutaneous Fistula: A Challenging Complication in Cervical Cancer Management"],"prefix":"10.7759","author":[{"given":"Abigayle","family":"Wyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mena","family":"Louis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwasemilore I","family":"Okunlola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raven","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2020.06.05","article-title":"Cervical cancer: epidemiology, risk factors and screening","volume":"32","author":"Zhang S","year":"2020","unstructured":"Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: epidemiology, risk factors and screening. Chin J Cancer Res. 2020, 32:720-8. 10.21147\/j.issn.1000-9604.2020.06.05","journal-title":"Chin J Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/v16091357","article-title":"Looking back, moving forward: challenges and opportunities for global cervical cancer prevention and control cervical cancer management","volume":"16","author":"Castle PE","year":"2024","unstructured":"Castle PE. Looking back, moving forward: challenges and opportunities for global cervical cancer prevention and control cervical cancer management. Viruses. 2024, 16:1357. 10.3390\/v16091357","journal-title":"Viruses"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2022.200238","article-title":"Cervical cancer therapies: current challenges and future perspectives","volume":"13","author":"Burmeister CA","year":"2022","unstructured":"Burmeister CA, Khan SF, Sch\u00e4fer G, Mbatani N, Adams T, Moodley J, Prince S. Cervical cancer therapies: current challenges and future perspectives. Tumour Virus Res. 2022, 13:200238. 10.1016\/j.tvr.2022.200238","journal-title":"Tumour Virus Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2016.1145208","article-title":"Bevacizumab for the treatment of cervical cancer","volume":"16","author":"Bizzarri N","year":"2016","unstructured":"Bizzarri N, Ghirardi V, Alessandri F, et al.. Bevacizumab for the treatment of cervical cancer. Expert Opin Biol Ther. 2016, 16:407-19. 10.1517\/14712598.2016.1145208","journal-title":"Expert Opin Biol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari KS","year":"2017","unstructured":"Tewari KS, Sill MW, Penson RT, et al.. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017, 390:1654-63. 10.1016\/S0140-6736(17)31607-0","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","volume":"36","author":"Lorusso D","year":"2025","unstructured":"Lorusso D, Colombo N, Dubot C, et al.. Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study. Ann Oncol. 2025, 36:65-75. 10.1016\/j.annonc.2024.10.002","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2023.34.e60","article-title":"Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer","volume":"34","author":"Kotaka S","year":"2023","unstructured":"Kotaka S, Kondo E, Kawai Y, et al.. Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer. J Gynecol Oncol. 2023, 34:60. 10.3802\/jgo.2023.34.e60","journal-title":"J Gynecol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-022-02196-8","article-title":"Incidence of fistula occurrence in patients with cervical cancer treated with bevacizumab: data from real-world clinical practice","volume":"27","author":"Sugiyama T","year":"2022","unstructured":"Sugiyama T, Katsumata N, Toita T, Ura M, Shimizu A, Kamijima S, Aoki D. Incidence of fistula occurrence in patients with cervical cancer treated with bevacizumab: data from real-world clinical practice. Int J Clin Oncol. 2022, 27:1517-28. 10.1007\/s10147-022-02196-8","journal-title":"Int J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7789","article-title":"Enterocutaneous fistula: a simplified clinical approach","volume":"12","author":"Tuma F","year":"2020","unstructured":"Tuma F, Crespi Z, Wolff CJ, Daniel DT, Nassar AK. Enterocutaneous fistula: a simplified clinical approach. Cureus. 2020, 12:7789. 10.7759\/cureus.7789","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2011.12.030","article-title":"Bevacizumab-associated fistula formation in postoperative colorectal cancer patients","volume":"214","author":"Ganapathi AM","year":"2012","unstructured":"Ganapathi AM, Westmoreland T, Tyler D, Mantyh CR. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. J Am Coll Surg. 2012, 214:582-8. 10.1016\/j.jamcollsurg.2011.12.030","journal-title":"J Am Coll Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ.S54192","article-title":"Chemotherapy-induced enterocutaneous fistula after perineal hernia repair using a biological mesh: a case report","volume":"7","author":"Eriksen M","year":"2014","unstructured":"Eriksen M, Bulut O. Chemotherapy-induced enterocutaneous fistula after perineal hernia repair using a biological mesh: a case report. Int Med Case Rep J. 2014, 7:11-3. 10.2147\/IMCRJ.S54192","journal-title":"Int Med Case Rep J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.15609","article-title":"Bevacizumab is associated with a higher gastrointestinal\/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy","volume":"167","author":"Yang ST","year":"2024","unstructured":"Yang ST, Liu HH, Liu CH, Wang LW, Wang PH. Bevacizumab is associated with a higher gastrointestinal\/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy. Int J Gynaecol Obstet. 2024, 167:80-7. 10.1002\/ijgo.15609","journal-title":"Int J Gynaecol Obstet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.05.031","article-title":"The risk of gastrointestinal perforation and\/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study","volume":"114","author":"Sfakianos GP","year":"2009","unstructured":"Sfakianos GP, Numnum TM, Halverson CB, Panjeti D, Kendrick JE 4th, Straughn JM Jr. The risk of gastrointestinal perforation and\/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. Gynecol Oncol. 2009, 114:424-6. 10.1016\/j.ygyno.2009.05.031","journal-title":"Gynecol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cps.2007.08.012","article-title":"Diagnosis and treatment of uncommon wounds","volume":"34","author":"Pozez AL","year":"2007","unstructured":"Pozez AL, Aboutanos SZ, Lucas VS. Diagnosis and treatment of uncommon wounds. Clin Plast Surg. 2007, 34:749-64. 10.1016\/j.cps.2007.08.012","journal-title":"Clin Plast Surg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13041003","article-title":"Risk factors for non-healing wounds-a single-centre study","volume":"13","author":"Wolny D","year":"2024","unstructured":"Wolny D, \u0160t\u011bp\u00e1nek L, Hor\u00e1kov\u00e1 D, Thomas J, Zapletalov\u00e1 J, Patel MS. Risk factors for non-healing wounds-a single-centre study. J Clin Med. 2024, 13:1003. 10.3390\/jcm13041003","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10151-022-02656-3","article-title":"Treatment of enterocutaneous fistula: a systematic review and meta-analysis","volume":"26","author":"Gefen R","year":"2022","unstructured":"Gefen R, Garoufalia Z, Zhou P, Watson K, Emile SH, Wexner SD. Treatment of enterocutaneous fistula: a systematic review and meta-analysis. Tech Coloproctol. 2022, 26:863-74. 10.1007\/s10151-022-02656-3","journal-title":"Tech Coloproctol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamasurg.153","article-title":"Definitive surgical treatment of enterocutaneous fistula: outcomes of a 23-year experience","volume":"148","author":"Owen RM","year":"2013","unstructured":"Owen RM, Love TP, Perez SD, et al.. Definitive surgical treatment of enterocutaneous fistula: outcomes of a 23-year experience. JAMA Surg. 2013, 148:118-26. 10.1001\/2013.jamasurg.153","journal-title":"JAMA Surg"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1580732","article-title":"Enterocutaneous fistula: Proven strategies and updates","volume":"29","author":"Gribovskaja-Rupp I","year":"2016","unstructured":"Gribovskaja-Rupp I, Melton GB. Enterocutaneous fistula: Proven strategies and updates. Clin Colon Rectal Surg. 2016, 29:130-7. 10.1055\/s-0036-1580732","journal-title":"Clin Colon Rectal Surg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2012.13.S1.S17","article-title":"Surgical management of enterocutaneous fistula","volume":"13","author":"Lee SH","year":"2012","unstructured":"Lee SH. Surgical management of enterocutaneous fistula. Korean J Radiol. 2012, 13:17-20. 10.3348\/kjr.2012.13.S1.S17","journal-title":"Korean J Radiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/369936-enterocutaneous-fistula-a-challenging-complication-in-cervical-cancer-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T22:43:39Z","timestamp":1751928219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/369936-enterocutaneous-fistula-a-challenging-complication-in-cervical-cancer-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.87475","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}